Evidence map›Paper›PMID 40145556›Full record

ArticleJHLT open2025

Pulmonary hypertension in Finland 2008-2020: A descriptive real-world cohort study (FINPAH).

Markku Pentikäinen, Piia Simonen, Helena Tuunanen, Pauliina Leskelä, Terttu Harju, Pertti Jääskeläinen, Christian Asseburg, Minna Oksanen, Erkki Soini, Christina Wennerström and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Markku PentikäinenHelsinki University Hospital and University of Helsinki, Helsinki, Finland.
Piia SimonenHelsinki University Hospital and University of Helsinki, Helsinki, Finland.
Helena TuunanenTurku University Hospital, Turku, Finland.
Pauliina LeskeläTampere University Hospital, Tampere, Finland.
Terttu HarjuOulu University Hospital, Oulu, Finland.
Pertti JääskeläinenKuopio University Hospital, Kuopio, Finland.
Christian AsseburgESiOR Oy, Kuopio, Finland.
Minna OksanenESiOR Oy, Kuopio, Finland.
Erkki SoiniESiOR Oy, Kuopio, Finland.
Christina WennerströmJanssen-Cilag AB, Solna, Sweden.
Airi PuhakkaJanssen-Cilag Oy, Espoo, Finland.
FINPAH study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To assess characteristics, risk group distribution, and prognosis of patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) in Finland. Methods: Clinical chart review of patients with PAH or CTEPH recorded between 2008 and 2019 and linkage to official mortality data. Results: We identified 627 patients, with 502 (80%) diagnosed after 2008, yielding an incidence of PAH and CTEPH of 4.0 and 2.9/million/year, respectively. The median time from symptoms to diagnosis was 1 year. Mean age at diagnosis of PAH patients ( Conclusions: Incidence and survival of PAH and CTEPH patients in Finland were similar to previously presented data for other countries.

Indexed as

chronic thromboembolic pulmonary hypertensionpulmonary arterial hypertensionreal-world evidenceregistry studysurvival

Identifiers

PMID40145556
PMCPMC11935358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.